Attovia files for a Nasdaq IPO under ticker ATTO, becoming the third biotech to file this month after Scribe and Apnimed.
The tally of biotechs waiting to list in the coming weeks has increased to three, after biologics maker Attovia Therapeutics filed for an initial public …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s…
Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of…
Scribe Therapeutics prices its Nasdaq IPO (SCTX), kicking off a wave of six biotechs expected to go public in the coming weeks.
Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.
From the co-founders of Turning Point, BlossomHill Therapeutics filed its IPO paperwork as it tests a macrocyclic small molecule…
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to…
